S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
NASDAQ:SCPH

scPharmaceuticals (SCPH) Stock Forecast, Price & News

$4.44
+0.05 (+1.14%)
(As of 05/13/2022 06:55 PM ET)
Add
Compare
Today's Range
$4.41
$4.68
50-Day Range
$4.39
$6.48
52-Week Range
$3.48
$7.28
Volume
23,100 shs
Average Volume
34,626 shs
Market Capitalization
$121.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.43
30 days | 90 days | 365 days | Advanced Chart
Receive SCPH News and Ratings via Email

Sign-up to receive the latest news and ratings for scPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

scPharmaceuticals logo

About scPharmaceuticals

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SCPH
Fax
N/A
Employees
26
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$2.06 per share

Profitability

Net Income
$-28.03 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
26,356,000
Market Cap
$121.53 million
Optionable
Not Optionable

Company Calendar

Last Earnings
3/22/2022
Today
5/16/2022
Next Earnings (Estimated)
5/18/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.15 out of 5 stars

Medical Sector

429th out of 1,403 stocks

Pharmaceutical Preparations Industry

178th out of 667 stocks

Analyst Opinion: 3.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -













scPharmaceuticals (NASDAQ:SCPH) Frequently Asked Questions

Is scPharmaceuticals a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for scPharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" scPharmaceuticals stock.
View analyst ratings for scPharmaceuticals
or view top-rated stocks.

When is scPharmaceuticals' next earnings date?

scPharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 18th 2022.
View our earnings forecast for scPharmaceuticals
.

How were scPharmaceuticals' earnings last quarter?

scPharmaceuticals Inc. (NASDAQ:SCPH) posted its quarterly earnings results on Tuesday, March, 22nd. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.34) by $0.07.
View scPharmaceuticals' earnings history
.

What price target have analysts set for SCPH?

2 brokers have issued 1-year price targets for scPharmaceuticals' stock. Their forecasts range from $5.00 to $15.00. On average, they anticipate scPharmaceuticals' stock price to reach $10.00 in the next year. This suggests a possible upside of 125.2% from the stock's current price.
View analysts' price targets for scPharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are scPharmaceuticals' key executives?
scPharmaceuticals' management team includes the following people:
  • Mr. John H. Tucker, Pres, CEO, Principal Exec. Officer, Principal Financial Officer & Director (Age 59, Pay $780.46k) (LinkedIn Profile)
  • Ms. Rachael Nokes, Sr. VP of Fin. & Principal Accounting Officer (Age 47, Pay $433.54k)
  • Katherine Taudvin, Director of Corp. Devel. & Investor Relations
  • Dr. John Mohr Pharm.D., Sr. VP of Clinical Devel. & Medical Affairs
  • Mr. Michael D. Hassman, Sr. VP of Technical Operations
What other stocks do shareholders of scPharmaceuticals own?
When did scPharmaceuticals IPO?

(SCPH) raised $96 million in an initial public offering on Friday, November 17th 2017. The company issued 6,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

What is scPharmaceuticals' stock symbol?

scPharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH."

Who are scPharmaceuticals' major shareholders?

scPharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include AIGH Capital Management LLC (5.10%), Renaissance Technologies LLC (0.68%), Belvedere Trading LLC (0.59%), Dimensional Fund Advisors LP (0.38%), Simplex Trading LLC (0.08%) and Envestnet Asset Management Inc. (0.04%). Company insiders that own scPharmaceuticals stock include 5Am Partners Iv, Llc, Andrew J Schwab, Jack A Khattar and John H Tucker.
View institutional ownership trends for scPharmaceuticals
.

Which institutional investors are selling scPharmaceuticals stock?

SCPH stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Envestnet Asset Management Inc..
View insider buying and selling activity for scPharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying scPharmaceuticals stock?

SCPH stock was bought by a variety of institutional investors in the last quarter, including Belvedere Trading LLC, AIGH Capital Management LLC, Simplex Trading LLC, and Dimensional Fund Advisors LP. Company insiders that have bought scPharmaceuticals stock in the last two years include Andrew J Schwab, Jack A Khattar, and John H Tucker.
View insider buying and selling activity for scPharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of scPharmaceuticals?

Shares of SCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is scPharmaceuticals' stock price today?

One share of SCPH stock can currently be purchased for approximately $4.44.

How much money does scPharmaceuticals make?

scPharmaceuticals has a market capitalization of $121.53 million. The company earns $-28.03 million in net income (profit) each year or ($1.03) on an earnings per share basis.

How many employees does scPharmaceuticals have?

scPharmaceuticals employs 26 workers across the globe.

What is scPharmaceuticals' official website?

The official website for scPharmaceuticals is www.scpharma.com.

How can I contact scPharmaceuticals?

scPharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The company can be reached via phone at (617) 517-0730 or via email at [email protected].

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.